Alpha Tau Medical (DRTS) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
17 Nov, 2026Platform and strategic focus
Alpha DaRT uses Radium-224 sources; its decay chain releases four alpha particles, with daughter atoms detaching in tumors and emitting radiation. Radium-224 half-life is ~3.7 days; the remaining chain’s total half-life is ~12 hours.
Alpha particles travel <100 μm in tissue, limiting healthy-tissue exposure but also tumor coverage; the technology is designed to distribute alpha emitters within tumors to address this limitation.
Target settings include localized unresectable or recurrent tumors, metastatic disease where immune effects are being explored, and high-unmet-need cancers including GBM and pancreatic cancer.
Development targets include SCC, head and neck SCC, prostate, liver, breast, GBM and pancreatic cancer; trials are underway in pancreas, liver, lung and prostate.
Clinical progress
Superficial-tumor experience spans hundreds of treated tumors; reported outcomes included a mild safety profile and marketing authorizations in Israel for skin or oral-cavity SCC and in Japan for unresectable locally advanced or recurrent head and neck cancer.
U.S. recurrent cSCC pilot: 10 patients treated, 22 reported adverse events, mostly mild or moderate, no treatment-related serious AEs and 100% complete response rate; the 88-patient pivotal study completed recruitment in May 2026.
Alpha DaRT plus pembrolizumab in recurrent or metastatic HNSCC: 11 recruited, 9 response-evaluable; systemic ORR 100% (4 CR, 5 PR), median OS 18.2 months and median PFS 5.4 months. Two device-related AEs were Grade 1; no device-related SAEs.
Pancreatic Phase I/II trials: 55 patients fully treated; DCR 87%, ORR 27%; treatment-associated AEs in 36%, Grade ≥3 in 9%, all Grade ≥3 events resolved, and no treatment-related deaths.
Interim recurrent GBM results in 3 patients: 2 CRs and 1 stable disease with a 30% decrease in tumor dimension; one Grade 3 associated SAE resolved with steroids. Enrollment target expanded to 20, with a 6-month survival interim analysis planned for Q1 2027.
Collaboration and commercial opportunity
Tolmar collaboration covers U.S. prostate cancer, with a U.S. bladder-cancer option; Alpha Tau retains non-urological indications and rights outside the U.S. Alpha Tau handles clinical development and manufacturing, while Tolmar holds U.S. commercialization rights.
Prostate terms include $20M equity at $11.99/share, a 25% premium to 30-day VWAP, and a $15M manufacturing investment at closing; up to $96.5M development and regulatory milestones and $65M commercial milestones.
Alpha DaRT supply to Tolmar is priced at 60% of net sales, subject to adjustments. The bladder option includes $5M equity, $5M for expanded manufacturing capacity and up to $96.5M in development and regulatory milestones.
Latest events from Alpha Tau Medical
- REGAIN: 100% feasibility, 5 complete responses among 6 assessed, and no local recurrence to date.DRTS
Study update - Strong clinical progress, U.S. partnership, and $104.8M cash drive expansion despite higher net loss.DRTS
Q2 2026 - Key cancer trials advance with pivotal data expected in 2026; strong financial position maintained.DRTS
Lytham Partners Spring 2026 Investor Conference - Alpha DaRT shows promising efficacy in solid tumors, with pivotal trials and FDA submission expected by 2027.DRTS
Investor presentation - Q1 2026 featured breakthrough clinical results, pivotal trial progress, and a $22.9M net loss.DRTS
Q1 2026 - Interim data showed 67% complete response and strong safety in recurrent GBM.DRTS
Study result - Up to $300M in securities offered to fund Alpha DaRT cancer therapy R&D and commercialization.DRTS
Registration filing - Japan approval, pivotal U.S. trials, and strong data set up a transformative year.DRTS
Sidoti March Small-Cap Virtual Conference - Alpha DaRT shows promising efficacy in solid tumors, with pivotal trials and global expansion ongoing.DRTS
Investor presentation